Intellia Therapeutics Inc

12 oct. 2026, 22:52 UTC

Intellia Therapeutics Inc advanced in after-market trading, settling 4.53% above its 20-day moving average and near the upper end of its one-month range.

9 oct. 2026, 20:07 UTC

Intellia Therapeutics Inc shares are advancing amid a broader market rally, regaining momentum after pulling back earlier in the session.

8 oct. 2026, 20:02 UTC

Intellia Therapeutics Inc shares are sharply higher, continuing an upward trend since Wednesday, currently positioned significantly above its 20-day moving average.

7 oct. 2026, 19:56 UTC

Intellia Therapeutics Inc shares fell sharply, reflecting broader biotechnology sector weakness and a decline in the ARK Genomic Revolution ETF amid notable volatility.

6 oct. 2026, 23:05 UTC

Intellia Therapeutics Inc is experiencing a slight increase in after-market trading, positioned near the upper end of its one-month range.

5 oct. 2026, 23:06 UTC

Intellia Therapeutics Inc's shares traded modestly lower during after-market hours, influenced by declines in Beam Therapeutics Inc and Recursion Pharmaceuticals Inc.

3 oct. 2026, 00:01 UTC

Intellia Therapeutics awarded inducement grants for 44.45k shares to new employees, with shares trading modestly lower in after-market hours.

2 oct. 2026, 23:11 UTC

Intellia Therapeutics Inc granted inducement awards of 44.45k restricted stock units to new employees, with the stock trading lower in after-market hours.

1 oct. 2026, 20:07 UTC

Intellia Therapeutics Inc is advancing during Thursday's session, gaining ground since Wednesday's close, despite pulling back from an earlier peak.

30 sept. 2026, 23:20 UTC

Intellia Therapeutics Inc is moving higher in after-market hours, supported by mixed economic indicators, including a revised GDP growth rate of 2.2% for Q2.

29 sept. 2026, 19:15 UTC

Intellia Therapeutics Inc is trading higher, rebounding after four consecutive declines, despite pulling back slightly from an earlier session peak.

28 sept. 2026, 23:11 UTC

Intellia Therapeutics Inc is seeing a modest increase in after-market trading, following a pullback earlier in the session, amid gains in CRISPR Therapeutics AG.

25 sept. 2026, 19:26 UTC

Shares of Prime Medicine Inc fell sharply despite FDA clearance for its gene-editing therapy, continuing a downward trend amid significant volatility.

24 sept. 2026, 19:46 UTC

Intellia Therapeutics Inc shares fell sharply after a weak pre-market start, remaining below the 20-day moving average and near the lower end of its one-month trading range.

23 sept. 2026, 22:11 UTC

Intellia Therapeutics Inc declined sharply in after-market trading, reaching its lowest point of the day and trading well below its 20-day moving average.

21 sept. 2026, 19:16 UTC

Intellia Therapeutics is advancing as it prepares to launch its hereditary angioedema treatment, lonvo-z, following positive Phase III study results.

18 sept. 2026, 23:11 UTC

Intellia Therapeutics Inc is experiencing a modest decline in after-market hours, trading near the lower end of its one-month range.

17 sept. 2026, 20:02 UTC

Intellia Therapeutics is advancing sharply, reflecting positive trends in biotechnology, while the ARK Genomic Revolution ETF gains from strong performances by Tempus AI and others.

16 sept. 2026, 23:11 UTC

Intellia Therapeutics Inc is trading higher in after-market hours, supported by stronger-than-expected U.S. retail sales data indicating robust consumer spending.

15 sept. 2026, 23:02 UTC

Intellia Therapeutics Inc shares are higher in after-market hours amid ongoing discussions about its Biologics License Application and market sentiment.

14 sept. 2026, 20:07 UTC

Intellia Therapeutics shares are higher, rebounding from earlier session lows amid a broader market recovery, though still below the 20-day moving average.

10 sept. 2026, 19:16 UTC

Intellia Therapeutics Inc shares are lower today, following a notable decline from Wednesday's close amid broader market sentiment after the ECB raised interest rates.

8 sept. 2026, 20:07 UTC

Intellia Therapeutics' shares decline despite FDA accepting its lonvo-z application for Priority Review, targeting a decision by March 2027.

3 sept. 2026, 19:16 UTC

Intellia Therapeutics shares are lower, reflecting sector pressure and a notable decline in first-quarter results. Correlated asset CRISPR Therapeutics also experienced a downturn.

1 sept. 2026, 20:09 UTC

Intellia Therapeutics is lower today, tracking broader market declines amid rising oil prices and increased U.S. Treasury yields, which raise inflation concerns.

31 août 2026, 23:21 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from recent declines and positioned above their 20-day moving average.

28 août 2026, 20:08 UTC

Intellia Therapeutics shares are lower today, continuing a recent downward trend amid rising U.S. Treasury yields and broader market weakness. No specific news was identified.

27 août 2026, 23:41 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from an earlier dip and surpassing their 20-day moving average. No specific news was identified.

26 août 2026, 23:11 UTC

Intellia Therapeutics Inc is higher in after-market hours, reflecting broader market gains. The asset remains above its 20-day moving average and near its one-month range.

25 août 2026, 20:09 UTC

Citizens reiterated its Market Outperform rating on Intellia Therapeutics and maintained a $30 price target, contributing to positive sentiment and higher shares.